Dimitris Papamargaritis
I am Associate Professor and Honorary Consultant in Diabetes and Endocrinology at University of Leicester/ University Hospitals of Northamptonshire NHS Group. My research interests include understanding how to best combine lifestyle, pharmacological and surgical treatments for management of obesity and type 2 diabetes. I am also interested in the mechanisms of weight loss, weight maintenance and diabetes remission after bariatric surgery and identifying potential treatments for postprandial hyperinsulinaemic hypoglycaemia. I am SCOPE certified, an EASO national fellow, an ASO UK Trustee and member of the ABCD academic committee.
Favourite way to be active
Playing tennis
Contact
dp421@leicester.ac.uk
Research Areas
pharmacotherapy, bariatric surgery, gut hormones, appetite, type 2 diabetes, obesity
Current Projects
· PI for CONTROL study: “The effect of Canagliflozin in patients without diabetes after bariatric surgery on glucose homeostasis.”
· Co- PI for BariEx study: “The effect of acute aerobic exercise on the time spent on hypoglycaemia after Roux-en-y gastric bypass.”
· PI for SALT study: “The effect of increased sodium intake with a carbohydrate-rich meal on glucose homeostasis in subjects without diabetes after bariatric surgery: A proof-of-concept, randomised, open-label, crossover study.”
· PI for CARLOTA study: “The impact of a fat-rich preload before a carbohydrate-rich meal on glucose homeostasis in patients without diabetes after sleeve gastrectomy: A proof-of-concept, randomized, open-label, crossover study.”
Publications
1. Melson E, Ashraf U, Papamargaritis D, Davies MJ. What is the pipeline for future medications for obesity? Int J Obes (Lond). 2024 Feb 1. PMID: 38302593
2. Papamargaritis D, le Roux CW, Holst JJ, Davies MJ. New therapies for obesity. Cardiovasc Res. 2024 Feb 17;119(18):2825-2842. PMID: 36448672
3. Yates T, Biddle GJH, Henson J, Edwardson CL, Arsenyadis F, Goff LM, Papamargaritis D, Webb DR, Khunti K, Davies MJ. Impact of weight loss and weight gain trajectories on body composition in a population at high risk of type 2 diabetes: A prospective cohort analysis. Diabetes Obes Metab. 2024 Mar;26(3):1008-1015. PMID: 38093678
4. Papamargaritis D, Al-Najim W, Lim JZM, Crane J, Bodicoat DH, Barber S, Lean M, McGowan B, O’Shea D, Webb DR, Wilding JPH, le Roux CW, Davies MJ. Effectiveness of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in weight management services (STRIVE study): a multicentre, open-label, parallel-group, randomized, controlled trial. Lancet Reg Health Eur 2024 Feb 9;39:100853